Evidence of Malignant Hyperthermia in Patients Administered Triggering Agents before Malignant Hyperthermia Susceptibility Identified: Missed Opportunities Prior to Diagnosis

Malignant hyperthermia (MH) is a hypermetabolic disorder of skeletal muscle triggered almost exclusively by potent inhalational agents and suxamethonium. Signs of an MH reaction are non-specific and may be confused with the presentation of other problems such as sepsis and overheating of a patient. A high index of suspicion is needed to be aware of an early presentation of MH. Nine patients are presented who showed abnormal signs with an earlier anaesthetic where the possible diagnosis of an MH reaction was missed. These patients either presented later with an MH reaction, confirmed by DNA analysis and in some cases in vitro contracture testing, or were diagnosed by the identification of a causative mutation confirming MH susceptibility. The MH clinical grading scale is helpful in determining the likelihood that clinical indicators indicate a possible MH reaction. Masseter muscle rigidity is a known sign of MH, confirmed in this report by positive in vitro contracture testing and DNA analysis. Several uncommon muscle disorders have a high association with MH, and postoperative myalgia unrelated to suxamethonium can be a sign which is associated with MH. These reports emphasise the importance of a thorough family history (as the MH status was known by the family in four patients), a high index of suspicion for MH, and documentation of the possibility of MH susceptibility in the anaesthesia record.

[1]  S. Treves,et al.  The Malignant Hyperthermia RYR1Y522S Mutation affects Calcium Homeostasis in Arterial Smooth Muscle Cells , 2016 .

[2]  C. Müller,et al.  European Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility. , 2015, British journal of anaesthesia.

[3]  P. Forget,et al.  The Changing Face of Malignant Hyperthermia: Less Fulminant, More Insidious , 2015, Anaesthesia and intensive care.

[4]  E. Lehman,et al.  Malignant Hyperthermia Deaths Related to Inadequate Temperature Monitoring, 2007–2012: A Report from The North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States , 2014, Anesthesia and analgesia.

[5]  C. Massey,et al.  Malignant Hyperthermia in Canada: Characteristics of Index Anesthetics in 129 Malignant Hyperthermia Susceptible Probands , 2014, Anesthesia and analgesia.

[6]  M. Roberts,et al.  Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis , 2013, Neuromuscular Disorders.

[7]  Keisaku Sato,et al.  Skeletal Muscle Ryanodine Receptor Mutations Associated with Malignant Hyperthermia Showed Enhanced Intensity and Sensitivity to Triggering Drugs when Expressed in Human Embryonic Kidney Cells , 2013, Anesthesiology.

[8]  H. Hamada,et al.  The severity of sevoflurane‐induced malignant hyperthermia , 2012, Acta anaesthesiologica Scandinavica.

[9]  D. Baralle,et al.  King–Denborough syndrome with and without mutations in the skeletal muscle ryanodine receptor (RYR1) gene , 2011, Neuromuscular Disorders.

[10]  K. Stowell,et al.  Identification of ryanodine receptor 1 single-nucleotide polymorphisms by high-resolution melting using the LightCycler 480 System. , 2008, Analytical biochemistry.

[11]  W. Ummenhofer,et al.  Re: masseter spasm after succinylcholine administration. , 2007, The Journal of emergency medicine.

[12]  H. Rosenberg,et al.  Orphanet Journal of Rare Diseases BioMed Central Review Malignant hyperthermia , 2007 .

[13]  R. Krivosic-Horber,et al.  Minor increase of endtidal CO2 during sevoflurane‐induced malignant hyperthermia , 2007, Paediatric anaesthesia.

[14]  G. Islander,et al.  Malignant hyperthermia and central core disease causative mutations in Swedish patients , 2007, Acta anaesthesiologica Scandinavica.

[15]  P. Allen,et al.  ENHANCED EXCITATION-COUPLED CALCIUM ENTRY IN MYOTUBES IS ASSOCIATED WITH EXPRESSION OF RYR 1 MH MUTATIONS , 2007 .

[16]  A. Beggs,et al.  X-Linked Myotubular and Centronuclear Myopathies , 2005, Journal of neuropathology and experimental neurology.

[17]  V. Pietrini,et al.  Adult onset multi/minicore myopathy associated with a mutation in the RYR1 gene , 2004, Journal of Neurology.

[18]  V. Pietrini,et al.  Mutations in the RYR1 gene in Italian patients at risk for malignant hyperthermia: evidence for a cluster of novel mutations in the C-terminal region. , 2002, Cell calcium.

[19]  P. Hopkins Malignant hyperthermia: advances in clinical management and diagnosis. , 2000, British journal of anaesthesia.

[20]  F. Chung,et al.  Succinylcholine‐associated postoperative myalgia , 2000, Anaesthesia.

[21]  L. Skovgaard,et al.  Analysis of anaesthesia in patients suspected to be susceptible to malignant hyperthermia before diagnostic in vitro contracture test , 1997, Acta anaesthesiologica Scandinavica.

[22]  P. Hopkins,et al.  Serum and urinary myoglobin following an aborted malignant hyperthermia reaction , 1996, Anaesthesia.

[23]  A. Localio,et al.  A Clinical Grading Scale to Predict Malignant Hyperthermia Susceptibility , 1994, Anesthesiology.

[24]  H. Rosenberg Trismus is not trivial. , 1987, Anesthesiology.

[25]  D. Moyes,et al.  Unexpected hyperthermia manifesting during outpatient anesthesia. , 1986, Anesthesiology.

[26]  M. Nahrwold,et al.  Masseter Spasm and Malignant Hyperthermia Are Not the Same Thing , 1986 .

[27]  A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. The European Malignant Hyperpyrexia Group. , 1984, British journal of anaesthesia.

[28]  Britt Ba Recent advances in malignant hyperthermia. , 1972 .

[29]  B. Britt Recent Advances in Malignant Hyperthermia , 1972, Anesthesia and analgesia.

[30]  Newson Aj Malignant hyperthermia: three case reports. , 1972 .

[31]  B. Britt,et al.  Malignant hyperthermia: A statistical review , 1970, Canadian Anaesthetists' Society journal.